CONTROL BIONICS LIMITEDCONTROL BIONICS LIMITEDCONTROL BIONICS LIMITED

CONTROL BIONICS LIMITED

No trades
See on Supercharts

CBL fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Control Bionics Ltd. engages in the manufacture, design, and sale of wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. It operates through the following segments: Australia, US, International, R&D, and Corporate. The Australia segment is involved with the sales of Trilogy units and components in Australia. The US segment refers to Manufacture and sales of Trilogy units and components in North America. The International segment deals with the activities undertaken to establish viable and additional operating segments. The R&D segment pertains to the Research activities undertaken regarding the Group's products. The Corporate segment offers support, regulatory and infrastructure activities, and elimination entries above the EBITDA line. The company was founded by Peter Shann Ford in 2005 and is headquartered in Sydney, Australia.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
CBL has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company